Clinical trials: Familial Primary Pulmonary Hypertension
Pulmonary Artery Hypertension
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.
- Trial name
- NCT04456998
- Testing
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Where
- 63 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Postpartum Hemorrhage \(PPH\), Postpartum Hemorrhage \(Primary\)
Safety and Effectiveness of the Alma System in Treating Primary Postpartum Hemorrhage
Postpartum Hemorrhage (PPH) is an obstetric emergency that can occur up to 24 hours after vaginal birth or cesarean section. In most cases, the uncontrolled bleeding is due to a lack of sufficient contraction of the uterus…
- Conditions
- Postpartum Hemorrhage \(PPH\), Postpartum Hemorrhage \(Primary\), PPH
- Trial name
- NCT06166771
- Testing
- Alma system
- Where
- Kenya
- Volunteers
- 10 people
- Sponsor
- ResQ Medical Ltd
Hypertension, Pulmonary Arterial Hypertension
Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH).
- Conditions
- Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension, Primary Pulmonary Hypertension
- Trial name
- T3PAH (NCT03528902)
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Hypertension
Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients
Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package parametric Doppler, TPD…
- Trial name
- NCT01913457
- Testing
- Ultrasound Doppler
- Where
- 2 sites in United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Echosense Ltd.
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Retrospective Data Analysis of Data From the Zurich PH Registry
The collected data from the Zurich Registry for pulmonary Hypertension (PH) are evaluated in a retrospective analysis. This study examines the number of patients and their exact diagnoses who are treated at the University…
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Artery Hypertension
- Trial name
- NCT03198910
- Where
- Switzerland
- Volunteers
- 313 people
- Sponsor
- University of Zurich
Primary Hypertension
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.
- Trial name
- NCT00882947
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded.
- Trial name
- BEAT OLE (NCT03657095)
- Testing
- Esuberaprost
- Where
- 45 sites in United States, Israel
- Volunteers
- 112 people
- Sponsor
- Lung Biotechnology PBC
Idiopathic Pulmonary Arterial Hypertension
Beta-blockers in i-PAH
The main question of this study is: 'Is selective beta-blocker treatment safe and effective in reducing sympathetic overdrive, thereby improving RV function and remodeling in patients with iPAH?'.
- Trial name
- NCT01246037
- Testing
- Bisoprolol
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Pharmacogenomics in Pulmonary Arterial Hypertension
Our goal is to determine clinically in Pulmonary Arterial Hypertension patients if associations exist between the efficacy and toxicity of sitaxsentan, bosentan, and ambrisentan and several gene polymorphisms in several key…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
- Trial name
- NCT00593905
- Testing
- Sitaxsentan, Bosentan, Ambrisentan
- Where
- United States
- Sponsor
- West Penn Allegheny Health System
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Pulmonary Hypertension Biorepository and Registry
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary
- Trial name
- PHBR (NCT04808596)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Kansas Medical Center
Idiopathic Pulmonary Arterial Hypertension
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
The current aims to combine analysis of different inflammatory biomarkers and BMPR2 mutations, which are currently analyzed in each patient diagnosed with idiopathic or familial PAH, to establish an earlier diagnosis and…
- Trial name
- NCT02959723
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Vascular Disorder, Pulmonary Artery Hypertension
HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)
To study the effect of SOT in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m on pulmonary artery…
- Conditions
- Pulmonary Vascular Disorder, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06084559
- Testing
- Supplemental oxygen therapy
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
- Trial name
- RARE-PAH (NCT05584722)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Vanderbilt University Medical Center
Hypertension, Pulmonary
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension
OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available. II.
- Trial name
- NCT00004754
- Testing
- epoprostenol
- Sponsor
- National Center for Research Resources (NCRR)
Pulmonary Artery Hypertension
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH
Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure.
- Trial name
- NCT03979482
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Laval University
Idiopathic Pulmonary Arterial Hypertension, Eisenmenger Syndrome
Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate
Due to vasodilatory properties of the NO, one of the therapeutic approaches for IPAH is oral use of nitric oxide precursors (10).
- Trial name
- NCT01683981
- Testing
- L-Citrulline Malate
- Where
- Iran
- Volunteers
- 25 people
- Sponsor
- Masih Daneshvari Hospital
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of…
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- NCT05462574
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Vanderbilt University Medical Center
Primary Pulmonary Hypertension
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
- Trial name
- INSPIRE (NCT03399604)
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 38 sites in United States
- Volunteers
- 121 people
- Sponsor
- Liquidia Technologies, Inc.